Phosphorylated c-Mpl tyrosine 591 regulates thrombopoietin-induced signaling

详细信息    查看全文

• 作者：Veena Sangkhae^a ; Sebastian Jonas Saur^b ; Alexis Kaushansky^c ; Kenneth Kaushansky^a ; Ian Stuart Hitchcock^b ; ^{ian.hitchcock@stonybrookmedicine.edu" class="auth_mail}
• 刊名：Experimental Hematology
• 出版年：June 2014
• 年：2014
• 卷：42
• 期：6
• 页码：477-486.e4
• 全文大小：1830 K

文摘

Thrombopoietin (TPO) is the primary regulator of platelet production, affecting cell survival, proliferation, and differentiation through binding to and stimulation of the cell surface receptor the cellular myeloproliferative leukemia virus oncogene (c-Mpl). Activating mutations in c-Mpl constitutively stimulate downstream signaling pathways, leading to aberrant hematopoiesis, and contribute to development of myeloproliferative neoplasms. Several studies have mapped the tyrosine residues within the cytoplasmic domain of c-Mpl that mediate these cellular signals; however, secondary signaling pathways are incompletely understood. In this study, we focused on c-Mpl tyrosine 591 (Y₅₉₁). We found Y₅₉₁ of wild-type c-Mpl to be phosphorylated in the presence of TPO. Additionally, eliminating Y₅₉₁ phosphorylation by mutation to Phe resulted in decreased total receptor phosphorylation. Using a Src homology 2/phosphotyrosine-binding (SH2/PTB) domain binding microarray, we identified novel c-Mpl binding partners for phosphorylated Y₅₉₁, including Src homology region 2 domain-containing phosphatase-1 (SHP-1), spleen tyrosine kinase (SYK) and Bruton's tyrosine kinase (BTK). The functional significance of binding partners was determined through small interfering RNA treatment of Ba/F3-Mpl cells, confirming that the increase in pERK1/2 resulting from removal of Y₅₉₁ may be mediated by spleen tyrosine kinase. These findings identify a novel negative regulatory pathway that controls TPO-mediated signaling, advancing our understanding of the mechanisms required for successful maintenance of hematopoietic stem cells and megakaryocyte development.